Stock News Buzz: Allergan plc (NYSE: AGN)

Allergan plc (NYSE: AGN) spotted trading -18.88% off 52-week high price. On the other end, the stock has been noted 39.84% away from the low price over the last 52-weeks. The stock changed 0.05% to recent value of $159.8. The stock transacted 4044393 shares during most recent day however it has an average volume of 4841.45K shares. The company has 327.91M of outstanding shares and 327.14M shares were floated in the market.  

Allergan plc (NYSE: AGN) announced today it received U.S. Food and Drug Administration (FDA) approval for the use of Juvéderm VOLUMA® XC, a hyaluronic acid gel dermal filler, with a TSK STERiGLIDE™ cannula for cheek augmentation to correct age-related volume deficit in the mid-face in adults over 21. A cannula is a thin, flexible tube with a rounded tip that can serve as an effective delivery system. Use of a cannula allows for injection of Juvéderm VOLUMA® XC in the cheek area. The TSK STERiGLIDE™ has a unique design compared to other cannulas available on the market and features a patented tip design with a near-tip delivery port for precise product placement.

“As a physician, I have used the Juvéderm Collection of Fillers for 13 years, so I am thrilled that the FDA has approved the use of cannula with Juvéderm VOLUMA® XC for mid-face volume deficit. With this latest approval, I have another effective option to provide volume and contour in the mid-face area. I can tailor my treatment approach for each patient while safely providing the aesthetic outcomes they wish to achieve,” says Dr. Dee Anna Glaser, a board-certified dermatologist in St. Louis and clinical trial investigator.

“At Allergan, we are committed to driving innovation in medical aesthetics as well as providing best-in-class injector training to our customers,” says Carrie Strom, Senior Vice President of U.S. Allergan Medical Aesthetics. “With this approval, Allergan will be able to educate on facial anatomy and injection techniques that will help healthcare providers administer treatment with Juvéderm VOLUMA® XC safely to achieve optimal patient satisfaction.”

A multicenter, split-face, investigator-blinded, non-inferiority study was performed to assess the safety and effectiveness of Juvéderm VOLUMA® XC for correction of age-related volume deficit in the mid-face with the use of a TSK STERiGLIDE™ cannula versus a needle. The 12-week study took place in seven sites across the U.S. with 60 subjects. All subjects completed the study. Results demonstrated comparable performance, safety profile and patient satisfaction between cannula and needle injection.

 Its earnings per share (EPS) expected to touch remained 24.90% for this year while earning per share for the next 5-years is expected to reach at 3.27%. AGN has a gross margin of 85.10% and an operating margin of -54.60% while its profit margin remained -54.20% for the last 12 months. 

 According to the most recent quarter its current ratio was 1 that represents company’s ability to meet its current financial obligations. The price moved ahead of 0.22% from the mean of 20 days, -0.65% from mean of 50 days SMA and performed 8.52% from mean of 200 days price. Company’s performance for the week was -0.26%, -0.76% for month and YTD performance remained 19.56%.

Leave a Reply

Your email address will not be published. Required fields are marked *